Literature DB >> 31808897

Inflammatory bone marrow microenvironment.

Nils B Leimkühler1, Rebekka K Schneider1.   

Abstract

Self-renewing hematopoietic stem cells and their progeny, lineage-specific downstream progenitors, maintain steady-state hematopoiesis in the bone marrow (BM). Accumulating evidence over the last few years indicates that not only primitive hematopoietic stem and progenitor cells (HSPCs), but also cells defining the microenvironment of the BM (BM niche), sense hematopoietic stress signals. They respond by directing and orchestrating hematopoiesis via not only cell-intrinsic but also cell-extrinsic mechanisms. Inflammation has many beneficial roles by activating the immune system in tissue repair and as a defense mechanism. However, chronic inflammation can have detrimental effects by stressing HSPCs, leading to cell (DNA) damage resulting in BM failure or even to leukemia. Emerging data have demonstrated that the BM microenvironment plays a significant role in the pathogenesis of hematopoietic malignancies, in particular, through disrupted inflammatory signaling, specifically in niche (microenvironmental) cells. Clonal selection in the context of microenvironmental alterations can occur in the context of toxic insults (eg, chemotherapy), not only aging but also inflammation. In this review, we summarize mechanisms that lead to an inflammatory BM microenvironment and discuss how this affects normal hematopoiesis. We pay particular attention to the process of aging, which is known to involve low-grade inflammation and is also associated with age-related clonal hematopoiesis and potentially malignant transformation.
© 2019 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31808897      PMCID: PMC6913454          DOI: 10.1182/hematology.2019000045

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  97 in total

1.  IFNγ induces monopoiesis and inhibits neutrophil development during inflammation.

Authors:  Alexander M de Bruin; Sten F Libregts; Marijke Valkhof; Louis Boon; Ivo P Touw; Martijn A Nolte
Journal:  Blood       Date:  2011-11-23       Impact factor: 22.113

2.  Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches.

Authors:  Ingrid G Winkler; Valérie Barbier; Robert Wadley; Andrew C W Zannettino; Sharon Williams; Jean-Pierre Lévesque
Journal:  Blood       Date:  2010-04-14       Impact factor: 22.113

Review 3.  Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies.

Authors:  Matthew R Warr; Eric M Pietras; Emmanuelle Passegué
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2011-03-15

Review 4.  Blood on the tracks: hematopoietic stem cell-endothelial cell interactions in homing and engraftment.

Authors:  Julie R Perlin; Audrey Sporrij; Leonard I Zon
Journal:  J Mol Med (Berl)       Date:  2017-07-13       Impact factor: 4.599

5.  IFN-γ-mediated hematopoietic cell destruction in murine models of immune-mediated bone marrow failure.

Authors:  Jichun Chen; Xingmin Feng; Marie J Desierto; Keyvan Keyvanfar; Neal S Young
Journal:  Blood       Date:  2015-10-21       Impact factor: 22.113

6.  Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia.

Authors:  Elena E Solomou; Katayoun Rezvani; Stephan Mielke; Daniela Malide; Keyvan Keyvanfar; Valeria Visconte; Sachiko Kajigaya; A John Barrett; Neal S Young
Journal:  Blood       Date:  2007-04-26       Impact factor: 22.113

Review 7.  Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment.

Authors:  Larisa V Kovtonyuk; Kristin Fritsch; Xiaomin Feng; Markus G Manz; Hitoshi Takizawa
Journal:  Front Immunol       Date:  2016-11-14       Impact factor: 7.561

8.  Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs.

Authors:  S Chen; N A Zambetti; E M J Bindels; K Kenswill; A M Mylona; N M Adisty; R M Hoogenboezem; M A Sanders; E M P Cremers; T M Westers; J H Jansen; A A van de Loosdrecht; M H G P Raaijmakers
Journal:  Leukemia       Date:  2016-04-25       Impact factor: 11.528

9.  Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.

Authors:  E A Eksioglu; X Chen; K-H Heider; B Rueter; K L McGraw; A A Basiorka; M Wei; A Burnette; P Cheng; J Lancet; R Komrokji; J Djeu; A List; S Wei
Journal:  Leukemia       Date:  2017-01-18       Impact factor: 11.528

10.  Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal stem cell-driven tissue regeneration.

Authors:  Mikaël M Martino; Kenta Maruyama; Gisela A Kuhn; Takashi Satoh; Osamu Takeuchi; Ralph Müller; Shizuo Akira
Journal:  Nat Commun       Date:  2016-03-22       Impact factor: 14.919

View more
  10 in total

1.  Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes.

Authors:  Laurent Schmied; Patricia A Olofsen; Pontus Lundberg; Alexandar Tzankov; Martina Kleber; Jörg Halter; Mario Uhr; Peter J M Valk; Ivo P Touw; Jakob Passweg; Beatrice Drexler
Journal:  Blood Adv       Date:  2020-11-10

2.  ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis.

Authors:  Roberta Taiane Germano de Oliveira; João Victor Alves Cordeiro; Bruna Ferreira Vitoriano; Mayara Magna de Lima Melo; Letícia Rodrigues Sampaio; Daniela de Paula Borges; Silvia Maria Meira Magalhães; Ronald Feitosa Pinheiro
Journal:  Med Oncol       Date:  2021-02-17       Impact factor: 3.064

3.  Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis.

Authors:  Meike Farber; Yiyang Chen; Lucas Arnold; Michael Möllmann; Eva Boog-Whiteside; Yu-An Lin; H Christian Reinhardt; Ulrich Dührsen; Maher Hanoun
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379

Review 4.  Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead.

Authors:  Basak Aru; Mojdeh Soltani; Cemil Pehlivanoglu; Ege Gürlü; Mazdak Ganjalikhani-Hakemi; Gülderen Yanikkaya Demirel
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 5.  Vascular Regulation of Hematopoietic Stem Cell Homeostasis, Regeneration, and Aging.

Authors:  Pradeep Ramalingam; Jason M Butler; Michael G Poulos
Journal:  Curr Stem Cell Rep       Date:  2021-09-04

6.  Pseudolycorine chloride ameliorates Th17 cell-mediated central nervous system autoimmunity by restraining myeloid-derived suppressor cell expansion.

Authors:  Gan Zhang; Xinying Zhu; Fan Yang; Juan Li; Xiao Leng; Chunfen Mo; Limei Li; Yantang Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

Review 7.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

Review 8.  Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia.

Authors:  Sarah S Burns; Reuben Kapur
Journal:  Stem Cell Reports       Date:  2020-08-11       Impact factor: 7.765

Review 9.  Putative Mechanisms Underlying Cardiovascular Disease Associated with Clonal Hematopoiesis of Indeterminate Potential.

Authors:  Sarah S Burns; Reuben Kapur
Journal:  Stem Cell Reports       Date:  2020-07-30       Impact factor: 7.765

10.  Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo.

Authors:  Johann-Christoph Jann; Maximilian Mossner; Vladimir Riabov; Eva Altrock; Nanni Schmitt; Johanna Flach; Qingyu Xu; Verena Nowak; Julia Obländer; Iris Palme; Nadine Weimer; Alexander Streuer; Ahmed Jawhar; Ali Darwich; Mohammad Jawhar; Georgia Metzgeroth; Florian Nolte; Wolf-Karsten Hofmann; Daniel Nowak
Journal:  Nat Commun       Date:  2021-10-25       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.